Osteoporosis in men: Its pathophysiology and the role of teriparatide in its treatment

Clinical Interventions in Aging

Volumn 3, Issue 4, 2008, Pages 635-645

  Gagnon, Claudia ^a   Li, Vivien ^a   Ebeling, Peter R ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Men; Osteoporosis; Parathyroid hormone; Pathophysiology; Treatment

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; DEOXYPYRIDINOLINE; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; PROCOLLAGEN; PYRIDINOLINE; VITAMIN D; ZOLEDRONIC ACID;

AGING; ALLERGIC REACTION; BONE DENSITY; BONE REMODELING; CALCIUM DEFICIENCY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CORTICAL BONE; DIZZINESS; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSPNEA; EXERCISE; FALL RISK; GENDER; HIP FRACTURE; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; INJECTION SITE HYPERSENSITIVITY; LEG CRAMP; LOW DRUG DOSE; MALE; MONOTHERAPY; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSARCOMA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT SATISFACTION; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; THORAX PAIN; TRABECULAR BONE; URTICARIA; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY; X RAY SPECTROMETRY;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FRACTURES, BONE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; TERIPARATIDE;

EID: 60749091264     PISSN: 11769092     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Aaron JE, Makins NB, Sagreiya K. 1987. The microanatomy of trabecular bone loss in normal aging men and women. Clin Orthop Relat Res, 215:260-71.
2. Adachl JD, Hanley DA, Lorraine JK, et al. 2007. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study. Clin Ther, 29, 2055-67.
3. Ahlborg HG, Johnell O, Turner CH, et al. 2003. Bone loss and bone size after menopause. N Engl J Med, 349, 327-34.
4. Amin S, Riggs BL, Atkinson EJ, et al. 2004. A potentially deleterious role of IGFBP-2 on bone density in aging men and women. J Bone Miner Res, 19:1075-83.
5. Amin S, Riggs BL, Melton LJ, 3rd, et al. 2007. High serum IGFBP-2 is predictive of increased bone turnover in aging men and women. J Bone Miner Res, 22:799-807.
6. Amin S, Zhang Y, Felson DT, et al. 2006. Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study. Am J Med, 119:426-33.
7. Balena R, Toolan BC, Shea M, et al. 1993. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest, 92, 2577-86.
8. Bellido T. 2006. Downregulation of SOST/sclerostin by PTH: a novel mechanism of hormonal control of bone formation mediated by osteocytes. J Musculoskelet Neuronal Interact, 6:358-9.
9. Bilezikian JP. 2000. Gender specificity and osteoporosis. J Gend Specif Med, 3:6-12.
10. Bilezikian JP. 2006. Osteonecrosis of the jaw - do bisphosphonates pose a risk? N Engl J Med, 355:2278-81.
11. Bilezikian JP. 2008. Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep, 6:24-30.
12. Black DM, Greenspan SL, Ensrud KE, et al. 2003. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med, 349:1207-15.
13. Burge R, Dawson-Hughes B, Solomon DH, et al. 2007. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res, 22, 465-75.
14. Burger H, Van Daele PL, Grashuis K, et al. 1997. Vertebral deformities and functional impairment in men and women. J Bone Miner Res, 12:152-7.
15. Canalis E, Centrella M, Burch W, et al. 1989. Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J Clin Invest, 83:60-5.
16. Carter ND, Kannus P, Khan KM. 2001. Exercise in the prevention of falls in older people: a systematic literature review examining the rationale and the evidence. Sports Med, 31:427-38.
17. Chang KP, Center JR, Nguyen TV, et al. 2004. Incidence of hip and other osteoporotic fractures in elderly men and women: Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res, 19:532-6.
18. Chen P, Miller PD, Delmas PD, et al. 2006. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res, 21:1785-90.
19. Cooper C, Melton LJ 3rd 1992. Epidemiology of osteoporosis. Trends Endocrinol Metab, 3:224-9.
20. Cramer JA, Amonkar MM, Hebborn A, et al. 2005. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin, 21:1453-60.
21. Dempster DW, Zhou H, Cosman F. 2001. PTH treatment directly stimulates bone formation in cancellous and cortical bone in humans. J Bone Miner Res, 16(S1):S179.
22. Dobnig H, Sipos A, Jiang Y, et al. 2005. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab, 90:3970-7.
23. Draper MW, Flowers DE, Huster WJ, et al. 1996. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res, 11:835-42.
24. Duque G, El Abdaimi K, Henderson JE, et al. 2004a. Vitamin D inhibits Fas ligand-induced apoptosis in human osteoblasts by regulating components of both the mitochondrial and Fas-related pathways. Bone, 35:57-64.
25. Duque G, Macoritto M, Dion N, et al. 2005. 1,25(OH)2D3 acts as a bone-forming agent in the hormone-independent senescence-accelerated mouse (SAM-P/6). Am J Physiol Endocrinol Metab, 288:E723-30.
26. Duque G, Macoritto M, Kremer R. 2004b. Vitamin D treatment of senescence accelerated mice (SAM-P/6) induces several regulators of stromal cell plasticity. Biogerontology, 5, 421-9.
27. Eastell R, Krege JH, Chen P, et al. 2006. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin, 22:61-6.
28. Ebeling PR. 1998. Osteoporosis in men. New insights into aetiology, pathogenesis, prevention and management. Drugs Aging, 13:421-34.
29. Ebeling PR. 2008. Clinical practice. Osteoporosis in men. N Engl J Med, 358:1474-82.
30. Ebeling PR, Akesson K. 2001. Role of biochemical markers in the management of osteoporosis. Best Pract Res Clin Rheumatol, 15:385-400.
31. Falahati-Nini A, Riggs BL, Atkinson EJ, et al. 2000. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest, 106:1553-60.
32. Finkelstein JS, Hayes A, Hunzelman JLet al. 2003. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med, 349:1216-26.
33. Finkelstein JS, LederBZ, Burnett SMet al. 2006. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab, 91:2882-7.
34. Garn SM, Frisancho AR, Sandusky ST, et al. 1972. Confirmation of the sex difference in continuing subperiosteal apposition. Am J Phys Anthropol, 36:377-80.
35. Goh SK, Yang KY, Koh JS, et al. 2007. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br, 89:349-53.
36. Gold DT, Pantos BS, Masica DN, et al. 2006. Initial experience with teriparatide in the United States. Curr Med Res Opin, 22:703-8.
37. Handler RP. 2008. Prior bisphosphonate therapy of osteoporosis attenuates and blocks response to subsequent parathyroid hormone. J Clin Rheumatol, 14:122-4.
38. Harper KD, Krege JH, Marcus R, et al. 2006. Comments on initial experience with teriparatide in the United States. Curr Med Res Opin, 22:1927.
39. Ho YV, Frauman AG, Thomson W, et al. 2000. Effects of alendronate on bone density in men with primary and secondary osteoporosis. Osteoporos Int, 11:98-101.
40. Hodsman A, Papaioannou A, Ann C. 2006. Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteopomsis. CMAJ, 175:48.
41. Jiang HX, Majumdar SR, Dick DA, et al. 2005. Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures. J Bone Miner Res, 20:494-500.
42. Jilka RL, Weinstein RS, Bellido T, et al. 1999. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest, 104:439-46.
43. Johnell O, Kanis J, Gullberg G. 2001. Mortality, morbidity, and assessment of fracture risk in male osteoporosis. Calcif Tissue Int, 69:182-4.
44. Kaufman JM, Orwoll E, Goemaere S, et al. 2005. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int, 16:510-6.
45. Khosla S, Amin S, Orwoll E. 2008. Osteoporosis in men. Endocr Rev, 29:441-64.
46. Khosla S, Melton LJ 3rd, Atkinson EJ, et al. 1998. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab, 83:2266-74.
47. Klotzbuecher CM, Ross PD, Landsman PB, et al. 2000. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res, 15:721-39.
48. Kukuljan S, Bass S, Salmon J, et al. 2006. Does calcium-vitamin D3 fortified milk enhance the effects of exercise on BMD in older men: An 18 month randomised controlled trial. J Bone Miner Res, 21:S184.
49. Kurland ES, Cosman F, McMahon DJ, et al. 2000. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab, 85:3069-76.
50. Kurland ES, Heller SL, Diamond B, et al. 2004. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int, 15:992-7.
51. Lau E, Ong K, Kurtz S, et al. 2008. Mortality following the diagnosis of a vertebral compression fracture in the Medicare population. J Bone Joint Surg Am, 90:1479-86.
52. Leder BZ, Leblanc KM, Schoenfeld DA, et al. 2003. Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab, 88:204-10.
53. Lenart BA, Lorich DG, Lane JM. 2008. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med, 358:1304-6.
54. Lips P. 2001. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev, 22:477-501.
55. Lord SR, Castell S, Corcoran J, et al. 2003. The effect of group exercise on physical functioning and falls in frail older people living in retirement villages: a randomized, controlled trial. J Am Geriatr Soc, 51:1685-92.
56. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. 2007. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med, 357:1799-809.
57. McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. 2004. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas, 48:271-87.
58. Melton LJ 3rd, Atkinson EJ, Cooper C, et al. 1999. Vertebral fractures predict subsequent fractures. Osteoporos Int, 10:214-21.
59. Meryn S. 2005. Undertreatment of osteoporosis in men. Arch Intern Med, 165:241.
60. Meunier PJ, Boivin G. 1997. Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications. Bone, 21:373-7.
61. Michaelsson K, Olofsson H, Jensevik K, et al. 2007. Leisure physical activity and the risk of fracture in men. PLoS Med, 4:e199.
62. Miller PD, Bilezikian JP, Diaz-Curiel M, et al. 2007. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab, 92:3535-41.
63. Miyakoshi N, Kasukawa Y, Linkhart TA, et al. 2001. Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology, 142:4349-56.
64. National Cancer Institute Surveillance Research Program. SEER Stat software version 6.1.4. 2001. Osteoporosis prevention, diagnosis, and therapy. JAMA, 285:785-95.
65. Neer R, Hayes A, Rao A, et al. 2002. Effects of parathyroid hormone, alendronate, or both on bone density in osteoporotic post-menopausal women. J Bone Miner Res, 17:S135.
66. Neer RM, Arnaud CD, Zanchetta JR, et al. 2001. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med, 344:1434-41.
67. Nevitt MC, Chen P, Kiel DP, et al. 2006. Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. Osteoporos Int, 17:1630-7.
68. Nishida S, Yamaguchi A, Tanizawa T, et al. 1994. Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone, 15:717-23.
69. Oreffo RO, Mundy GR, Seyedin SM, et al. 1989. Activation of the bone-derived latent TGF beta complex by isolated osteoclasts. Biochem Biophys Res Commun, 158:817-23.
70. Orwoll E, Ettinger M, Weiss S, et al. 2000. Alendronate for the treatment of osteoporosis in men. N Engl J Med, 343:604-10.
71. Orwoll ES, Klein R. 2001. Osteoporosis in men. Epidemiology, pathophysiology, and clinical characterization. In: Marcus, R., Feldman, D., Kelsey, J. (ed.) Osteoporosis. 2nd ed. San Diego: Academic Press.
72. Orwoll E, Lambert LC, Marshall LM, et al. 2006. Testosterone and estradiol among older men. J Clin Endocrinol Metab, 91:1336-44.
73. Orwoll ES, Scheele WH, Paul S, et al. 2003. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res, 18:9-17.
74. Quattrocchi E, Kourlas H. 2004. Teriparatide: a review. Clin Ther, 26:841-54.
75. Reeve J, Meunier PJ, Parsons JA, et al. 1980. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J, 280:1340-4.
76. Riggs BL, Melton LJ, Robb RA, et al. 2008. A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res, 23:205-14.
77. Ringe JD, Faber H, Farahmand P, et al. 2006. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int, 26:427-31.
78. Scane AC, Francis RM, Sutcliffe AM, et al. 1999. Case-control study of the pathogenesis and sequelae of symptomatic vertebral fractures in men. Osteoporos Int, 9:91-7.
79. Seeman E. 2002. Pathogenesis of bone fragility in women and men. Lancet, 359:1841-50.
80. Silva MJ, Gibson LJ. 1997. Modeling the mechanical behavior of vertebral trabecular bone: effects of age-related changes in microstructure. Bone, 21:191-9.
81. Stroup J, Kane 0MP, Abu-Baker AM. 2008. Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm, 65:532-9.
82. Stroup J, Kane MP, Busch RS. 2003. Pharmacist-run teriparatide clinic. Am J Health Syst Pharm, 60:2247-9.
83. Tam CS, Heersche JN, Murray TM, et al. 1982. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology, 110:506-12.
84. Tang BM, Eslick GD, Nowson C, et al. 2007. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet, 370:657-66.
85. Tinetti ME. 2003. Clinical practice. Preventing falls in elderly persons. N Engl J Med, 348:42-9.
86. Vieth R, Chan PC, MacFarlane GD. 2001. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr, 73:288-94.
87. Visekruna M, Wilson D, McKiernan FE. 2008. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab, 93:2948-52.